Table 1 Baseline clinical characteristics in Studies 1199 and 1036

Age, median (range), years

60 (11−83)

59 (10−92)

Male sex, n (%)

139 (60)

672 (60)

ECOG performance status,^a n (%)

 0

87 (38)

420 (37)

 1

114 (50)

521 (46)

 2

24 (10)

135 (12)

 3

3 (1)

33 (3)

 4

0

5 (<1)

Time since original diagnosis, median (range), weeks

186 (12–773)

171 (3−1584)

Maximum prior imatinib dose,^b n (%)

  ≤ 400 mg

71 (31)

353 (31)

  > 400–600 mg

58 (25)

212 (19)

  > 600–800 mg

99 (43)

532 (47)

  > 800 mg

2 (1)

24 (2)

Outcome with prior imatinib therapy,^c n (%)

 PD within 6 months of start

30 (13)

153 (14)

 PD beyond 6 months of start

181 (79)

871 (77)

 Intolerance

19 (8)

99 (9)

Best response to prior imatinib,^d n (%)

 CR

8 (3)

56 (5)

 PR

82 (36)

353 (31)

 Stable disease

93 (40)

391 (35)

 PD

39 (17)

288 (26)

 Not applicable

7 (3)

31 (3)